Charlotte Lecerf1, Maud Kamal2, Sophie Vacher3, Walid Chemlali4, Anne Schnitzler5, Claire Morel6, Coraline Dubot7, Emmanuelle Jeannot8, Didier Meseure9, Jerzy Klijanienko10, Odette Mariani11, Edith Borcoman12, Valentin Calugaru13, Nathalie Badois14, Anne Chilles15, Maria Lesnik16, Samar Krhili17, Olivier Choussy18, Caroline Hoffmann19, Eliane Piaggio20, Ivan Bieche21, Christophe Le Tourneau22. 1. Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France. Electronic address: charlotte.lecerf@curie.fr. 2. Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France. Electronic address: maud.kamal@curie.fr. 3. Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: sophie.vacher@curie.fr. 4. Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: walid.chemlali@curie.fr. 5. Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: anne.schnitzler@curie.fr. 6. Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France. Electronic address: claire.morel@curie.fr. 7. Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France. Electronic address: coraline.dubot@curie.fr. 8. Department of Genetics, Institut Curie, PSL Research University, Paris, France; Department of Pathology, Institut Curie, PSL Research University, Paris, France. Electronic address: emmanuelle.jeannot@curie.fr. 9. Department of Pathology, Institut Curie, PSL Research University, Paris, France. Electronic address: didier.meseure@curie.fr. 10. Department of Pathology, Institut Curie, PSL Research University, Paris, France. Electronic address: jerzy.klijanienko@curie.fr. 11. Department of Pathology, Institut Curie, PSL Research University, Paris, France. Electronic address: Odette.mariani@curie.fr. 12. INSERM U932 Research Unit, Institut Curie, PSL Research University, Paris, France. Electronic address: edith.borcoman@curie.fr. 13. Department of Radiotherapy, Institut Curie, PSL Research University, Paris, France. Electronic address: valentin.calugaru@curie.fr. 14. Department of Surgery, Institut Curie, PSL Research University, Paris, France. Electronic address: nathalie.badois@curie.fr. 15. Department of Radiotherapy, Institut Curie, PSL Research University, Paris, France. Electronic address: anne.chilles@curie.frm. 16. Department of Surgery, Institut Curie, PSL Research University, Paris, France. Electronic address: maria.lesnik@curie.fr. 17. Department of Surgery, Institut Curie, PSL Research University, Paris, France. Electronic address: samar.krhili@curie.fr. 18. Department of Surgery, Institut Curie, PSL Research University, Paris, France. Electronic address: olivier.choussy@curie.fr. 19. INSERM U932 Research Unit, Institut Curie, PSL Research University, Paris, France; Department of Surgery, Institut Curie, PSL Research University, Paris, France. Electronic address: caroline.hoffmann@curie.fr. 20. INSERM U932 Research Unit, Institut Curie, PSL Research University, Paris, France. Electronic address: eliane.piaggio@curie.fr. 21. Department of Genetics, Institut Curie, PSL Research University, Paris, France; EA7331, Paris Descartes University, Faculty of Pharmaceutical and Biological Sciences, Paris, France. Electronic address: ivan.bieche@curie.fr. 22. Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France; INSERM U900 Research Unit, Institut Curie, Saint-Cloud, France; Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France. Electronic address: christophe.letourneau@curie.fr.
Abstract
BACKGROUND: Nivolumab and pembrolizumab targeting programmed cell death protein 1 (PD-1) have recently been approved among patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who failed platinum therapy. We aimed to evaluate the prognostic value of selected immune gene expression in HNSCC. PATIENTS AND METHODS: We retrospectively assessed the expression of 46 immune-related genes and immune-cell subpopulation genes including immune checkpoints by real-time polymerase chain reaction among 96 patients with HNSCC who underwent primary surgery at Institut Curie between 1990 and 2006. Univariate and multivariate analyses were performed to assess the prognostic value of dysregulated genes. RESULTS: The Median age of the population was 56 years [range: 35-78]. Primary tumour location was oral cavity (45%), oropharynx (21%), larynx (18%) and hypopharynx (17%). Twelve patients (13%) had an oropharyngeal human papillomavirus-positive tumour. Most significantly overexpressed immune-related genes were TNFRSF9/4-1BB (77%), IDO1 (75%), TNFSF4/OX40L (74%) and TNFRSF18/GITR (74%), and immune-cell subpopulation gene was FOXP3 (62%). Eighty-five percent of tumours analysed overexpressed actionable immunity genes, including PD-1/PD-L1, TIGIT, OX40/OX40L and/or CTLA4. Among the immune-related genes, high OX40L mRNA level (p = 0.0009) and low PD-1 mRNA level (p = 0.004) were associated with the highest risk of recurrence. Among the immune-cell subpopulation genes, patients with high PDGFRB mRNA level (p < 0.0001) and low CD3E (p = 0.0009) or CD8A mRNA levels (p = 0.004) were also at the highest risk of recurrence. CONCLUSIONS: OX40L and PDGFRB overexpression was associated with poor outcomes, whereas PD-1 overexpression was associated with good prognosis in patients with HNSCC treated with primary surgery, suggesting their relevance as potential prognostic biomarkers and major therapeutic targets.
BACKGROUND: Nivolumab and pembrolizumab targeting programmed cell death protein 1 (PD-1) have recently been approved among patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who failed platinum therapy. We aimed to evaluate the prognostic value of selected immune gene expression in HNSCC. PATIENTS AND METHODS: We retrospectively assessed the expression of 46 immune-related genes and immune-cell subpopulation genes including immune checkpoints by real-time polymerase chain reaction among 96 patients with HNSCC who underwent primary surgery at Institut Curie between 1990 and 2006. Univariate and multivariate analyses were performed to assess the prognostic value of dysregulated genes. RESULTS: The Median age of the population was 56 years [range: 35-78]. Primary tumour location was oral cavity (45%), oropharynx (21%), larynx (18%) and hypopharynx (17%). Twelve patients (13%) had an oropharyngeal human papillomavirus-positive tumour. Most significantly overexpressed immune-related genes were TNFRSF9/4-1BB (77%), IDO1 (75%), TNFSF4/OX40L (74%) and TNFRSF18/GITR (74%), and immune-cell subpopulation gene was FOXP3 (62%). Eighty-five percent of tumours analysed overexpressed actionable immunity genes, including PD-1/PD-L1, TIGIT, OX40/OX40L and/or CTLA4. Among the immune-related genes, high OX40L mRNA level (p = 0.0009) and low PD-1 mRNA level (p = 0.004) were associated with the highest risk of recurrence. Among the immune-cell subpopulation genes, patients with high PDGFRB mRNA level (p < 0.0001) and low CD3E (p = 0.0009) or CD8A mRNA levels (p = 0.004) were also at the highest risk of recurrence. CONCLUSIONS:OX40L and PDGFRB overexpression was associated with poor outcomes, whereas PD-1 overexpression was associated with good prognosis in patients with HNSCC treated with primary surgery, suggesting their relevance as potential prognostic biomarkers and major therapeutic targets.
Authors: Nathan J Mackenzie; Clarissa Nicholls; Abby R Templeton; Mahasha Pj Perera; Penny L Jeffery; Kate Zimmermann; Arutha Kulasinghe; Tony J Kenna; Ian Vela; Elizabeth D Williams; Patrick B Thomas Journal: Clin Transl Immunology Date: 2022-06-26
Authors: Kyriakos Chatzopoulos; Sotiris Sotiriou; Andrea R Collins; Panagiotis Kartsidis; Alessandra C Schmitt; Xianfeng Chen; Khashayarsha Khazaie; Michael L Hinni; Colleen A Ramsower; Matthew A Zarka; Samir H Patel; Joaquin J Garcia Journal: Head Neck Pathol Date: 2020-10-03